Recent 8-K filings for ANGO
Highest-materiality recent filing
AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%
- Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
- Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.
-
Filed patent infringement lawsuit against Endovascular Engineering on April 23, 2026 in Delaware District Court.
-
AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance
Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.
-
CEO James C. Clemmer to retire by Nov 30, 2026; retention awards for NEOs
Clemmer will step down as CEO upon successor appointment or Nov 30, 2026; may extend month-to-month; to serve as consultant for one year.
-
AngioDynamics CEO presents at J.P. Morgan conference; slide content not disclosed in filing
President & CEO Jim Clemmer presented at J.P. Morgan 44th Annual Healthcare Conference on Jan 14, 2026.
-
AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%
Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.
-
AngioDynamics shareholders elect two Class I directors, ratify auditor, approve say-on-pay
James C. Clemmer and Michael E. Tarnoff, MD elected as Class I directors with ~29.6M and ~29.2M votes for.
-
AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance
Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.
-
AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%
Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
-
AngioDynamics enters $25M secured revolving credit facility with JPMorgan Chase
Secured $25 million revolving credit facility from JPMorgan Chase, maturing May 28, 2027.
-
AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY
Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.
-
AngioDynamics hosts virtual Cardiovascular Investor Event on April 2, 2025
Event presentation slides furnished as Exhibit 99.1, but no specific financial or operational updates disclosed in filing.
-
AngioDynamics CEO presents at J.P. Morgan conference; no material financial updates
James Clemmer, President & CEO, presented at J.P. Morgan 43rd Annual Healthcare Conference on Jan 16, 2025.
-
AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M
Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).
-
AngioDynamics hosts NanoKnife IRE Prostate event; no material financial data
Virtual investor event on NanoKnife IRE for prostate held January 8, 2025.
-
Elected three Class III directors: Burgess, Johnson, Licitra each with >24.8M votes for, 5.99M broker non-votes.
-
AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11
Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).
-
AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment
Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.
-
AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M
Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.
-
Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.
-
AngioDynamics settles patent litigation with BD; $7M upfront, $2.5M annual minimums
One-time payment of $7M to BD, with $3M due within 5 business days and remainder over 12 months.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.68 · Most common event earnings